Loss of CD73-mediated actin polymerization promotes endometrial tumor progression

Journal of Clinical Investigation

Volumn 126, Issue 1, 2016, Pages 220-238

  Bowser, Jessica L ^a   Blackburn, Michael R ^b   Shipley, Gregory L ^b   Molina, Jose G ^b   Dunner, Kenneth ^a   Broaddus, Russell R ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; ACTIN RELATED PROTEIN 2-3 COMPLEX; ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); BETA CATENIN; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; F ACTIN; MESSENGER RNA; NEURAL WISKOTT ALDRICH SYNDROME PROTEIN; PROTEIN CDC42; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; UVOMORULIN; ACTIN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; NT5E PROTEIN, HUMAN;

ACTIN POLYMERIZATION; ADVANCED CANCER; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL ADHESION; CELL CONTACT; CELL FUNCTION; CELL INVASION; CELL MIGRATION; COMPARATIVE STUDY; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DOWN REGULATION; ENDOMETRIUM CARCINOMA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN INDUCTION; ANIMAL; C57BL MOUSE; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL MOTION; DISEASE COURSE; ENDOMETRIAL NEOPLASMS; IMMUNOLOGY; METABOLISM; METASTASIS; PATHOLOGY; PHYSIOLOGY; PROTEIN MULTIMERIZATION; PSEUDOPODIUM; TUMOR CELL LINE; TUMOR INVASION;

5'-NUCLEOTIDASE; ACTINS; ANIMALS; CDC42 GTP-BINDING PROTEIN; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE PROGRESSION; ENDOMETRIAL NEOPLASMS; FEMALE; GPI-LINKED PROTEINS; HUMANS; MICE; MICE, INBRED C57BL; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROTEIN MULTIMERIZATION; PSEUDOPODIA; RECEPTOR, ADENOSINE A1;

EID: 84956688103     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI79380     Document Type: Article

References (110)

1. Zimmermann H. 5'-Nucleotidase: molecular structure and functional aspects. Biochem J. 1992;285(pt 2):345-365.
2. Antonioli L, Pacher P, Vizi ES, Hasko G. CD39 and CD73 in immunity and inflammation. Trends Mol Med. 2013;19(6):355-367.
3. Stagg J, et al. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci U S A. 2010;107(4):1547-1552.
4. Jin D, et al. CD73 on tumor cells impairs antitumor T-cell responses: A novel mechanism of tumor-induced immune suppression. Cancer Res. 2010;70(6):2245-2255.
5. Stagg J, et al. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res. 2011;71(8):2892-2900.
6. Wang L, et al. CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. J Clin Invest. 2011;121(6):2371-2382.
7. Yegutkin GG, et al. Altered purinergic signaling in CD73-deficient mice inhibits tumor progression. Eur J Immunol. 2011;41(5):1231-1241.
8. Stagg J, et al. CD73-deficient mice are resistant to carcinogenesis. Cancer Res. 2012;72(9):2190-2196.
9. Zhi X, et al. RNA interference of ecto-5'-nucleotidase (CD73) inhibits human breast cancer cell growth and invasion. Clin Exp Metastasis. 2007;24(6):439-448.
10. Zhou P, et al. Overexpression of Ecto-5'-nucleotidase (CD73) promotes T-47D human breast cancer cells invasion and adhesion to extracellular matrix. Cancer Biol Ther. 2007;6(3):426-431.
11. Wang L, et al. Ecto-5'-nucleotidase promotes invasion, migration and adhesion of human breast cancer cells. J Cancer Res Clin Oncol. 2008;134(3):365-372.
12. Zhi X, et al. RNAi-mediated CD73 suppression induces apoptosis and cell-cycle arrest in human breast cancer cells. Cancer Sci. 2010;101(12):2561-2569.
13. Ujhazy P, et al. Evidence for the involvement of ecto-5'-nucleotidase (CD73) in drug resistance. Int J Cancer. 1996;68(4):493-500.
14. Quezada C, et al. 5'-ectonucleotidase mediates multiple-drug resistance in glioblastoma multiforme cells. J Cell Physiol. 2013;228(3):602-608.
15. Loi S, et al. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc Natl Acad Sci U S A. 2013;110(27):11091-11096.
16. Ohta A, et al. A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci U S A. 2006;103(35):13132-13137.
17. Colgan SP, Eltzschig HK, Eckle T, Thompson LF. Physiological roles for ecto-5'-nucleotidase (CD73). Purinergic Signal. 2006;2(2):351-360.
18. Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature. 2001;414(6866):916-920.
19. Linden J. Adenosine in tissue protection and tissue regeneration. Mol Pharmacol. 2005;67(5):1385-1387.
20. Madara JL, et al. 5'-adenosine monophosphate is the neutrophil-derived paracrine factor that elicits chloride secretion from T84 intestinal epithelial cell monolayers. J Clin Invest. 1993;91(5):2320-2325.
21. Eckle T, et al. Cardioprotection by ecto-5'-nucleotidase (CD73) and A2B adenosine receptors. Circulation. 2007;115(12):1581-1590.
22. Lennon PF, Taylor CT, Stahl GL, Colgan SP. Neutrophil-derived 5'-adenosine monophosphate promotes endothelial barrier function via CD73-mediated conversion to adenosine and endothelial A2B receptor activation. J Exp Med. 1998;188(8):1433-1443.
23. Eltzschig HK, et al. Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors. J Exp Med. 2003;198(5):783-796.
24. Thompson LF, et al. Crucial role for ecto-5'-nucleotidase (CD73) in vascular leakage during hypoxia. J Exp Med. 2004;200(11):1395-1405.
25. Synnestvedt K, et al. Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Invest. 2002;110(7):993-1002.
26. Blay J, White TD, Hoskin DW. The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res. 1997;57(13):2602-2605.
27. Wang L, et al. Ecto-5'-nucleotidase (CD73) promotes tumor angiogenesis. Clin Exp Metastasis. 2013;30(5):671-680.
28. Allard B, Turcotte M, Spring K, Pommey S, Royal I, Stagg J. Anti-CD73 therapy impairs tumor angiogenesis. Int J Cancer. 2014;134(6):1466-1473.
29. Koszalka P, et al. Inhibition of CD73 stimulates the migration and invasion of B16F10 melanoma cells in vitro, but results in impaired angiogenesis and reduced melanoma growth in vivo. Oncol-Rep. 2014;31(2):819-827.
30. Allard B, Turcotte M, Stagg J. CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growth. J Biomed Biotechnol. 2012;2012:485156.
31. Silverberg SG. Problems in the differential diagnosis of endometrial hyperplasia and carcinoma. Mod Pathol. 2000;13(3):309-327.
32. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R. Uterine papillary serous carcinoma: A highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol. 1982;6(2):93-108.
33. Kandoth C, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67-73.
34. Kuramoto H, Tamura S, Notake Y. Establishment of a cell line of human endometrial adenocarcinoma in vitro. Am J Obstet Gynecol. 1972;114(8):1012-1019.
35. Mayor S, Riezman H. Sorting GPI-anchored proteins. Nat Rev Mol Cell Biol. 2004;5(2):110-120.
36. Partridge MA, Marcantonio EE. Initiation of attachment and generation of mature focal adhesions by integrin-containing filopodia in cell spreading. Mol Biol Cell. 2006;17(10):4237-4248.
37. Galbraith CG, Yamada KM, Galbraith JA. Polymerizing actin fibers position integrins primed to probe for adhesion sites. Science. 2007;315(5814):992-995.
38. Yonemura S, Itoh M, Nagafuchi A, Tsukita S. Cell-to-cell adherens junction formation and actin filament organization: similarities and differences between non-polarized fibroblasts and polarized epithelial cells. J Cell Sci. 1995;108(pt 1):127-142.
39. Vasioukhin V, Bauer C, Yin M, Fuchs E. Directed actin polymerization is the driving force for epithelial cell-cell adhesion. Cell. 2000;100(2):209-219.
40. Costa M, Raich W, Agbunag C, Leung B, Hardin J, Priess JR. A putative catenin-cadherin system mediates morphogenesis of the Caenorhabditis elegans embryo. J Cell Biol. 1998;141(1):297-308.
41. Raich WB, Agbunag C, Hardin J. Rapid epithelial-sheet sealing in the Caenorhabditis elegans embryo requires cadherin-dependent filopodial priming. Curr Biol. 1999;9(20):1139-1146.
42. Tanaka-Matakatsu M, Uemura T, Oda H, Takeichi M, Hayashi S. Cadherin-mediated cell adhesion and cell motility in Drosophila trachea regulated by the transcription factor Escargot. Development. 1996;122(12):3697-3705.
43. Martin-Blanco E, Pastor-Pareja JC, Garcia-Bellido A. JNK and decapentaplegic signaling control adhesiveness and cytoskeleton dynamics during thorax closure in Drosophila. Proc Natl Acad Sci U S A. 2000;97(14):7888-7893.
44. Jacinto A, Wood W, Balayo T, Turmaine M, Martinez-Arias A, Martin P. Dynamic actin-based epithelial adhesion and cell matching during Drosophila dorsal closure. Curr Biol. 2000;10(22):1420-1426.
45. Vasioukhin V, Fuchs E. Actin dynamics and cellcell adhesion in epithelia. Curr Opin Cell Biol. 2001;13(1):76-84.
46. Pansare V, et al. Increased expression of hypoxia-inducible factor 1alpha in type I and type II endometrial carcinomas. Mod Pathol. 2007;20(1):35-43.
47. Kong T, Westerman KA, Faigle M, Eltzschig HK, Colgan SP. HIF-dependent induction of adenosine A2B receptor in hypoxia. FASEB J. 2006;20(13):2242-2250.
48. Linden J. Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol. 2001;41:775-787.
49. Nachmias VT, Philp N, Momoyama Y, Choi JK. G-actin pool and actin messenger RNA during development of the apical processes of the retinal pigment epithelial cells of the chick. Dev Biol. 1992;149(2):239-246.
50. Lewis JE, et al. Cross-talk between adherens junctions and desmosomes depends on plakoglobin. J Cell Biol. 1997;136(4):919-934.
51. Takenawa T, Suetsugu S. The WASP-WAVE protein network: connecting the membrane to the cytoskeleton. Nat Rev Mol Cell Biol. 2007;8(1):37-48.
52. Nobes CD, Hall A. Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell. 1995;81(1):53-62.
53. Miki H, Sasaki T, Takai Y, Takenawa T. Induction of filopodium formation by a WASP-related actin-depolymerizing protein N-WASP. Nature. 1998;391(6662):93-96.
54. Rohatgi R, et al. The interaction between N-WASP and the Arp2/3 complex links Cdc42-dependent signals to actin assembly. Cell. 1999;97(2):221-231.
55. McNeill H, Ozawa M, Kemler R, Nelson WJ. Novel function of the cell adhesion molecule uvomorulin as an inducer of cell surface polarity. Cell. 1990;62(2):309-316.
56. Rackley RR, et al. 5'-nucleotidase activity in prostatic carcinoma and benign prostatic hyperplasia. Cancer Res. 1989;49(13):3702-3707.
57. Durak I, Isik AC, Canbolat O, Akyol O, Kavutcu M. Adenosine deaminase, 5' nucleotidase, xanthine oxidase, superoxide dismutase, and catalase activities in cancerous and noncancerous human laryngeal tissues. Free Radic Biol Med. 1993;15(6):681-684.
58. Eroglu A, Canbolat O, Demirci S, Kocaoglu H, Eryavuz Y, Akgül H. Activities of adenosine deaminase and 5'-nucleotidase in cancerous and noncancerous human colorectal tissues. Med Oncol. 2000;17(4):319-324.
59. Leth-Larsen R, et al. Metastasis-related plasma membrane proteins of human breast cancer cells identified by comparative quantitative mass spectrometry. Mol Cell Proteomics. 2009;8(6):1436-1449.
60. Supernat A, et al. CD73 expression as a potential marker of good prognosis in breast carcinoma. Appl Immunohistochem Mol Morphol. 2012;20(2):103-107.
61. Aliagas E, Vidal A, Texido L, Ponce J, Condom E, Martin-Satue M. High expression of ecto-nucleotidases CD39 and CD73 in human endometrial tumors. Mediators Inflamm. 2014;2014:509027.
62. Wang H, et al. NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity. Br J Cancer. 2012;106(8):1446-1452.
63. Kruger KH, Thompson LF, Kaufmann M, Moller P. Expression of ecto-5'-nucleotidase (CD73) in normal mammary gland and in breast carcinoma. Br J Cancer. 1991;63(1):114-118.
64. Zhi X, Wang Y, Yu J, Zhang L, Yin L, Zhou P. Potential prognostic biomarker CD73 regulates epidermal growth factor receptor expression in human breast cancer. IUBMB Life. 2012;64(11):911-920.
65. Sorlie T, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869-10874.
66. Gordon LA, Mulligan KT, Maxwell-Jones H, Adams M, Walker RA, Jones JL. Breast cell invasive potential relates to the myoepithelial phenotype. Int J Cancer. 2003;106(1):8-16.
67. Roy S, et al. Rare somatic cells from human breast tissue exhibit extensive lineage plasticity. Proce Natl Acad Sci U S A. 2013;110(12):4598-4603.
68. Bono MR, Fernandez D, Flores-Santibanez F, Rosemblatt M, Sauma D. CD73 and CD39 ectonucleotidases in T cell differentiation: beyond immunosuppression. FEBS Lett. 2015;589(22):3454-3560.
69. Mandapathil M, et al. Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J Biol Chem. 2010;285(10):7176-7186.
70. Ohta A, Kini R, Ohta A, Subramanian M, Madasu M, Sitkovsky M. The development and immunosuppressive functions of CD4(+) CD25(+) FoxP3(+) regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway. Front Immunol. 2012;3:190.
71. Ohta A, Sitkovsky M. Extracellular adenosinemediated modulation of regulatory T cells. Front Immunol. 2014;5:304.
72. Panjehpour M, Castro M, Klotz KN. Human breast cancer cell line MDA-MB-231 expresses endogenous A2B adenosine receptors mediating a Ca2+ signal. Br J Pharmacol. 2005;145(2):211-218.
73. Strohmeier GR, Reppert SM, Lencer WI, Madara JL. The A2b adenosine receptor mediates cAMP responses to adenosine receptor agonists in human intestinal epithelia. J Biol Chem. 1995;270(5):2387-2394.
74. Louis NA, Robinson AM, MacManus CF, Karhausen J, Scully M, Colgan SP. Control of IFN-αA by CD73: implications for mucosal inflammation. J Immunol. 2008;180(6):4246-4255.
75. Burnstock G, Boeynaems JM. Purinergic signalling and immune cells. Purinergic Signal. 2014;10(4):529-564.
76. Feoktistov I, et al. Differential expression of adenosine receptors in human endothelial cells: role of A2B receptors in angiogenic factor regulation. Circ Res. 2002;90(5):531-538.
77. Umapathy SN, et al. Adenosine A1 receptors promote vasa vasorum endothelial cell barrier integrity via Gi and Akt-dependent actin cytoskeleton remodeling. PLoS One. 2013;8(4):e59733.
78. Leclerc BG, et al. CD73 expression is an independent prognostic factor in prostate cancer [published online ahead of print August 7, 2015]. Clin Cancer Res. doi:10.1158/1078-0432.CCR-15-1181.
79. Borghese F, Clanchy FI. CD74: an emerging opportunity as a therapeutic target in cancer and autoimmune disease. Expert Opin Ther Targets. 2011;15(3):237-251.
80. Linke B, et al. The tolerogenic function of annexins on apoptotic cells is mediated by the annexin core domain. J Immunol. 2015;194(11):5233-5242.
81. Hsiao YW, et al. CCAAT/enhancer binding protein delta in macrophages contributes to immunosuppression and inhibits phagocytosis in nasopharyngeal carcinoma. Sci Signal. 2013;6(284):ra59.
82. Stein R, et al. CD74: A new candidate target for the immunotherapy of B-cell neoplasms. Clin Cancer Res. 2007;13(18 pt 2):5556s-5563s.
83. Cheah MT, et al. CD14-expressing cancer cells establish the inflammatory and proliferative tumor microenvironment in bladder cancer. Proc Natl Acad Sci U S A. 2015;112(15):4725-4730.
84. Bremer E. Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy. ISRN Oncol. 2013;2013:371854.
85. Karrasch T, Jobin C. Wound healing responses at the gastrointestinal epithelium: A close look at novel regulatory factors and investigative approaches. Zeitschrift fur Gastroenterologie. 2009;47(12):1221-1229.
86. Karhausen J, Furuta GT, Tomaszewski JE, Johnson RS, Colgan SP, Haase VH. Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. J Clin Invest. 2004;114(8):1098-1106.
87. Bynoe MS, Waickman AT, Mahamed DA, Mueller C, Mills JH, Czopik A. CD73 is critical for the resolution of murine colonic inflammation. J Biomed Biotechnol. 2012;2012:260983.
88. Turner JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol. 2009;9(11):799-809.
89. Hatfield SM, et al. Immunological mechanisms of the antitumor effects of supplemental oxygenation. Sci Transl Med. 2015;7(277):277ra30.
90. Atkinson WB, Gusberg SB. Histochemical studies on abnormal growth of human endometrium; alkaline phosphatase in hyperplasia and adenocarcinoma. Cancer. 1948;1(2):248-251.
91. Nozawa S, et al. Heat-stable alkaline phosphatase in uterine cancer, with special reference to its histochemical heat-stability and the L-phenylalanine inhibition test. Histochem J. 1981;13(6):941-951.
92. Loffler M, Morote-Garcia JC, Eltzschig SA, Coe IR, Eltzschig HK. Physiological roles of vascular nucleoside transporters. Arterioscler Thromb Vasc Biol. 2007;27(5):1004-1013.
93. Eltzschig HK, et al. HIF-1-dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia. J Exp Med. 2005;202(11):1493-1505.
94. Comerford KM, Lawrence DW, Synnestvedt K, Levi BP, Colgan SP. Role of vasodilator-stimulated phosphoprotein in PKA-induced changes in endothelial junctional permeability. FASEB J. 2002;16(6):583-585.
95. Lawrence DW, Comerford KM, Colgan SP. Role of VASP in reestablishment of epithelial tight junction assembly after Ca2+ switch. Am J Physiol Cell Physiol. 2002;282(6):C1235-C1245.
96. Aherne CM, et al. Epithelial-specific A2B adenosine receptor signaling protects the colonic epithelial barrier during acute colitis. Mucosal Immunol. 2015;8(3):699.
97. Panther E, et al. Expression and function of adenosine receptors in human dendritic cells. FASEB J. 2001;15(11):1963-1970.
98. Kim M, Chen SW, Park SW, D'Agati VD, Yang J, Lee HT. Kidney-specific reconstitution of the A1 adenosine receptor in A1 adenosine receptor knockout mice reduces renal ischemia-reperfusion injury. Kidney Int. 2009;75(8):809-823.
99. Hoelzle MK, Svitkina T. The cytoskeletal mechanisms of cell-cell junction formation in endothelial cells. Mol Biol Cell. 2012;23(2):310-323.
100. Hotulainen P, et al. Defining mechanisms of actin polymerization and depolymerization during dendritic spine morphogenesis. J Cell Biol. 2009;185(2):323-339.
101. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev. 2001;53(4):527-552.
102. Chen L, Zhang JJ, Huang XY. cAMP inhibits cell migration by interfering with Rac-induced lamellipodium formation. J Biol Chem. 2008;283(20):13799-13805.
103. Krause M, Dent EW, Bear JE, Loureiro JJ, Gertler FB. Ena/VASP proteins: regulators of the actin cytoskeleton and cell migration. Annu Rev Cell Dev Biol. 2003;19:541-564.
104. Harbeck B, Huttelmaier S, Schluter K, Jockusch BM, Illenberger S. Phosphorylation of the vasodilator-stimulated phosphoprotein regulates its interaction with actin. J Biol Chem. 2000;275(40):30817-30825.
105. Skoble J, Auerbuch V, Goley ED, Welch MD, Portnoy DA. Pivotal role of VASP in Arp2/3 complexmediated actin nucleation, actin branch-formation, and Listeria monocytogenes motility. J Cell Biol. 2001;155(1):89-100.
106. Blackburn MR, Vance CO, Morschl E, Wilson CN. Adenosine receptors and inflammation. Handb Exp Pharmacol. 2009;(193):215-269.
107. Mills JH, Alabanza L, Weksler BB, Couraud PO, Romero IA, Bynoe MS. Human brain endothelial cells are responsive to adenosine receptor activation. Purinergic Signal. 2011;7(2):265-273.
108. Yu W, Zacharia LC, Jackson EK, Apodaca G. Adenosine receptor expression and function in bladder uroepithelium. Am J Physiol Cell Physiol. 2006;291(2):C254-C265.
109. Aliagas E, et al. Changes in expression and activity levels of ecto-5'-nucleotidase/CD73 along the mouse female estrous cycle. Acta Physiol (Oxf). 2010;199(2):191-197.
110. Mendoza-Rodriguez CA, Gonzalez-Mariscal L, Cerbon M. Changes in the distribution of ZO-1, occludin, and claudins in the rat uterine epithelium during the estrous cycle. Cell Tissue Res. 2005;319(2):315-330.